JonesTrading analyst Soumit Roy maintained a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report) today and set a price target of $22.00. The company's shares closed yesterday at $6.18.Roy covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Aeglea Biotherapeutics, and Adicet Bio. According to TipRanks, Roy has an average return of 5.2% and a 33.59% success rate on recommended stocks. Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $27.00, which is a 336.89% upside from current levels. In a report released today, B.Riley Financial also initiated coverage with a Buy rating on the stock with a $16.00 price target.
https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Nov 2022 à Déc 2022 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Déc 2021 à Déc 2022 Plus de graphiques de la Bourse Actinium Pharmaceuticals